SCCM Resource Library-The Med, the Myth, the Legend

Video Transcription

Video Summary

In this video, Ankit Sakooja discusses two potentially nephrotoxic medications: the combination therapy of vancomycin with piperosalintazobactam (PIPTAZ), and furosemide. The myth surrounding the combination therapy is that it increases the risk of acute kidney injury (AKI), but studies have shown that any increase in AKI is predominantly mild or stage 1, and there is no increased risk of moderate to severe AKI. As for furosemide, it has been wrongly believed to cause AKI, but studies have shown that it does not lead to an increased need for acute dialysis or mortality. Furthermore, avoiding or treating fluid overload with diuretics is beneficial and does not cause AKI.

Asset Subtitle

Pharmacology, 2023

Asset Caption

Type: one-hour concurrent | Everyday Villains: Drugs as Kidney Toxins (SessionID 1217960)

Meta Tag

Content Type Presentation

Knowledge Area Pharmacology

Membership Level Professional

Membership Level Select

Tag Pharmacology

Year 2023

Keywords

nephrotoxic medications

vancomycin with piperosalintazobactam

furosemide

acute kidney injury

fluid overload

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.